Skip to main content
Equibles
IONS logo

IONS · Ionis Pharmaceuticals Inc

Track IONS — free

Use IONS with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$58.09 -0.04 (-0.07%) At close · Sep 4
Russell 1000 member Rebalance outlook locked
Market Cap
$9.65B
Shares
166.18M

Options Calculator

Theoretical estimate

Estimate what a long-dated option on IONS could return if you hold it and the stock reaches a target price. Premiums are theoretical Black-Scholes-Merton values — tune the inputs to match your broker, then compare each strike's return against simply holding the shares.

Holding period

2.00 years

Implied volatility (%)

Implied volatility from the IONS options chain (Sep 18, 2026) — the market's own forward-looking estimate.Market-wide VIX 14.5.

Risk-free rate (%)

Latest SOFR (2026-09-03) — an overnight rate, a rough proxy over years.

Dividend per share

Annualizes to a 0% yield. No cash dividends on file — set an amount to model one.

Target price at horizon

Spot $58.09 at close 2026-09-04.

Best strike
—
Highest estimated return
Return at target
—
— annualized
Breakeven
—
Stock price to break even
Hold the stock
—
— annualized, with dividends

Return by strike at your target price

Strike ladder

Strike Moneyness Premium Breakeven Value at target Return Annualized Max loss

Per share; one contract = 100 shares. Premiums are theoretical Black-Scholes-Merton estimates — real options are American-style and priced off an implied-volatility smile, so use your broker's quote for the actual premium. Not investment advice.

Loading strategy simulator…
Key facts CIK 874015 CUSIP 462222100 13F (30d) 368 filings 356 filers Visit website Investor relations